Published in J Pharmacol Exp Ther on February 02, 2004
Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS. Neurosci Biobehav Rev (2008) 1.52
HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse. J Neurochem (2006) 1.31
Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol (2011) 1.29
Molecular targets of opiate drug abuse in neuroAIDS. Neurotox Res (2005) 1.16
Kappa opioids as potential treatments for stimulant dependence. AAPS J (2005) 1.08
Proteomic analysis of the effects of cocaine on the enhancement of HIV-1 replication in normal human astrocytes (NHA). Brain Res (2006) 0.99
HIV-1 gp120 and drugs of abuse: interactions in the central nervous system. Curr HIV Res (2012) 0.98
HIV and recent illicit drug use interact to affect verbal memory in women. J Acquir Immune Defic Syndr (2013) 0.95
Proteomic analyses of methamphetamine (METH)-induced differential protein expression by immature dendritic cells (IDC). Biochim Biophys Acta (2007) 0.93
Cocaine and HIV-1 interplay: molecular mechanisms of action and addiction. J Neuroimmune Pharmacol (2011) 0.93
Drugs of abuse and HIV infection/replication: implications for mother-fetus transmission. Life Sci (2010) 0.87
Cocaine potentiates cathepsin B secretion and neuronal apoptosis from HIV-infected macrophages. J Neuroimmune Pharmacol (2014) 0.83
Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors. Int Rev Neurobiol (2014) 0.81
Molecular and contextual markers of hepatitis C virus and drug abuse. Mol Diagn Ther (2009) 0.80
Bioinformatics models in drug abuse and Neuro-AIDS: Using and developing databases. Bioinformation (2006) 0.79
Polymorphisms of the kappa opioid receptor and prodynorphin genes: HIV risk and HIV natural history. J Acquir Immune Defic Syndr (2013) 0.77
Differential targeting of Gbetagamma-subunit signaling with small molecules. Science (2006) 2.96
Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin Microbiol Rev (2008) 2.88
Role of microglia in central nervous system infections. Clin Microbiol Rev (2004) 2.69
Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin Microbiol Rev (2009) 1.90
Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus. J Immunol (2005) 1.88
Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors. J Med Chem (2003) 1.62
Morphine induces apoptosis of human microglia and neurons. Neuropharmacology (2002) 1.61
Globalization: a new dimension for academic internal medicine. Am J Med (2006) 1.50
Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia (2005) 1.49
Prolonged microglial cell activation and lymphocyte infiltration following experimental herpes encephalitis. J Immunol (2008) 1.48
Opioid G protein-coupled receptors: signals at the crossroads of inflammation. Trends Immunol (2003) 1.45
Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors. J Med Chem (2006) 1.37
Effects of mixed-action kappa/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology (2003) 1.35
Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology (2005) 1.34
Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling. Nat Neurosci (2010) 1.30
Interleukin-10 attenuates production of HSV-induced inflammatory mediators by human microglia. Glia (2004) 1.26
Toll-like receptors in defense and damage of the central nervous system. J Neuroimmune Pharmacol (2007) 1.24
Microglia as a pharmacological target in infectious and inflammatory diseases of the brain. J Neuroimmune Pharmacol (2006) 1.23
Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem (2003) 1.22
Morphine potentiates HIV-1 gp120-induced neuronal apoptosis. J Infect Dis (2005) 1.20
A novel Gbetagamma-subunit inhibitor selectively modulates mu-opioid-dependent antinociception and attenuates acute morphine-induced antinociceptive tolerance and dependence. J Neurosci (2008) 1.20
Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proc Natl Acad Sci U S A (2012) 1.19
Microglial cells initiate vigorous yet non-protective immune responses during HSV-1 brain infection. Virus Res (2006) 1.18
Differential responses of human brain cells to West Nile virus infection. J Neurovirol (2005) 1.17
In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice. J Pharmacol Exp Ther (2010) 1.17
Mycobacterium tuberculosis-induced cytokine and chemokine expression by human microglia and astrocytes: effects of dexamethasone. J Infect Dis (2005) 1.17
2-aminothiazole-derived opioids. Bioisosteric replacement of phenols. J Med Chem (2004) 1.16
TNF-alpha-induced chemokine production and apoptosis in human neural precursor cells. J Leukoc Biol (2005) 1.14
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors. J Med Chem (2007) 1.13
Glycosylation improves the central effects of DAMGO. Chem Biol Drug Des (2007) 1.11
High-level expression of functional chemokine receptor CXCR4 on human neural precursor cells. Brain Res Dev Brain Res (2004) 1.09
Cocaine-induced HIV-1 expression in microglia involves sigma-1 receptors and transforming growth factor-beta1. Int Immunopharmacol (2006) 1.08
CXCL10 production from cytomegalovirus-stimulated microglia is regulated by both human and viral interleukin-10. J Virol (2003) 1.08
Neural precursor cell susceptibility to human cytomegalovirus diverges along glial or neuronal differentiation pathways. J Neurosci Res (2005) 1.07
Reactive oxygen species drive herpes simplex virus (HSV)-1-induced proinflammatory cytokine production by murine microglia. J Neuroinflammation (2011) 1.05
Early detection of central nervous system tuberculosis with the gen-probe nucleic Acid amplification assay: utility in an inner city hospital. Clin Infect Dis (2002) 1.05
Herpes simplex virus induces neural oxidative damage via microglial cell Toll-like receptor-2. J Neuroinflammation (2010) 1.05
10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors. J Med Chem (2004) 1.04
Intracerebral infection with murine cytomegalovirus induces CXCL10 and is restricted by adoptive transfer of splenocytes. J Neurovirol (2004) 1.03
Serial testing of refugees for latent tuberculosis using the QuantiFERON-gold in-tube: effects of an antecedent tuberculin skin test. Am J Trop Med Hyg (2009) 1.03
Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons. Glia (2010) 1.02
Chronic cortical and subcortical pathology with associated neurological deficits ensuing experimental herpes encephalitis. Brain Pathol (2009) 1.02
CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonist. Neuropharmacology (2007) 1.02
Murine cytomegalovirus infection of neural stem cells alters neurogenesis in the developing brain. PLoS One (2011) 1.01
Cocaine alters proliferation, migration, and differentiation of human fetal brain-derived neural precursor cells. J Pharmacol Exp Ther (2006) 1.01
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 3: 8-Thiocarboxamido and 8-thioformamido derivatives of cyclazocine. Bioorg Med Chem Lett (2005) 1.01
Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties. J Pharmacol Exp Ther (2005) 1.01
New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem (2006) 1.00
Dysregulated interferon-gamma responses during lethal cytomegalovirus brain infection of IL-10-deficient mice. Virus Res (2007) 1.00
Differential apoptotic signaling in primary glial cells infected with herpes simplex virus 1. J Neurovirol (2006) 0.99
Antimicrobial resistance in Escherichia coli causing urinary tract infections in Costa Rica: a clinical dilemma. Int J Antimicrob Agents (2003) 0.98
In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties. Neurochem Res (2008) 0.97
Several delta-opioid receptor ligands display no subtype selectivity to the human delta-opioid receptor. Eur J Pharmacol (2002) 0.97
Toll-like receptor 2 signaling is a mediator of apoptosis in herpes simplex virus-infected microglia. J Neuroinflammation (2007) 0.96
Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore. ACS Chem Neurosci (2010) 0.96
Activation of Toll-like receptors inhibits herpes simplex virus-1 infection of human neuronal cells. J Neurosci Res (2009) 0.96
WIN55,212-2-mediated inhibition of HIV-1 expression in microglial cells: involvement of cannabinoid receptors. J Neuroimmune Pharmacol (2006) 0.96
8-Carboxamidocyclazocine: a long-acting, novel benzomorphan. J Pharmacol Exp Ther (2002) 0.96
Memory T cells persisting in the brain following MCMV infection induce long-term microglial activation via interferon-γ. J Neurovirol (2011) 0.95
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 5. Opioid receptor binding properties of N-((4'-phenyl)-phenethyl) analogues of 8-CAC. Bioorg Med Chem Lett (2007) 0.95
Synthesis and pharmacological evaluation of 6,7-indolo/thiazolo-morphinans--further SAR of levorphanol. J Med Chem (2007) 0.94
Effects of the mixed-action kappa/mu opioid agonist 8-carboxamidocyclazocine on cocaine- and food-maintained responding in rhesus monkeys. Eur J Pharmacol (2004) 0.94